A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-29

Study Completion Date

2027-01-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MR-linac Guided Adaptive Radiotherapy for Inoperable Mediastinal Tumor

NCT05163509

Mediastinal Tumor

UNKNOWN PHASE2

Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver

NCT01030757

Liver Cancer

TERMINATED PHASE2

Magnetic Resonance Imaging for Lung Radiotherapy

NCT04275921

Cancer Lung Cancer

UNKNOWN NA

Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer

NCT06604533

Abdominal Cancer

RECRUITING NA

Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases

NCT02933242

Metastatic Tumors

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Stereotactic Ablative Radiotherapy (SABR) for tumours in the thorax and abdomen is becoming the standard of care for patients with small, localised disease. Recent publications and guidelines provide evidence for safe, effective treatment prescriptions in most of these tumour sites. However this guidance is based on the use of x-ray based guidance systems, without the use of functional imaging or real-time adaptation. To investigate the potential benefits of MRI-guided SABR, including superior at-treatment imaging, gating, real-time adaptation and the integration of functional or biological information, the investigators propose to undertake MR-guided SABR using established guidance. In doing this the investigators will be able to evaluate the patient experience (for example the MR Linac is considerably noisier than a standard treatment machine); the investigators will be able to acquire images (with no additional radiation) to interrogate motion, and deformations in real-time to assess whether or not real time adaptations would benefit the patient experience and/or outcomes; the investigators will be able to compare the outcomes of the patients treated on a machine with superior imaging to those undergoing the same (or similar) treatment on standard machines using the UKCAT database; the investigators will be able (should participants choose to give consent) to acquire research images interrogating tumour and normal tissue physiology/biology and determine if and how this information may be able to improve treatments and/or predict response. For these reasons it is important to make this change in practice (from x-ray guided SABR to MRI-guided SABR) within the confines of an observational clinical study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Cancer Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have no MRI contra-indications.
2. Eligible for abdominal SABR in accordance with the NHSE SABR Consortium Guidelines or eligible for central lung SABR in accordance with RTOG Guidelines.
3. Be able to give informed consent.
4. Anticipated life-expectancy \> 6 months.
5. Not more than 3 oligmetastatic sites treated in total per patients.
6. Performance status ≤ 2.
7. Willing to attend follow-up and have details collected on prospective basis for a minimum of 1 year.

Exclusion Criteria

1. Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
2. Unable to tolerate MRI scans.
3. Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator make it undesirable for the patient to participate in the study.
4. Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make it undesirable for the patient to participate in the study.
5. Any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No